Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine before HSCT in pediatric advanced MDS or JMML
NL-OMON41785Phase 2Recruiting
- Sponsor
- Celgene Corporation
- Start
- Jun 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of azacitidine in myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML), sponsored by Celgene Corporation. Primary endpoint: Response rate at Cycle 3 Day 28. Started Jun 2016; status: recruiting.
02
Drugs
azacitidine
03
Conditions
myelodysplastic syndrome (MDS)juvenile myelomonocytic leukemia (JMML)
Beyond the preview
Go deeper on NL-OMON41785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41785.